1
|
Herman CE, Min L, Choe LH, Maurer RW, Xu X, Ghose S, Lee KH, Lenhoff AM. Analytical characterization of host-cell-protein-rich aggregates in monoclonal antibody solutions. Biotechnol Prog 2023; 39:e3343. [PMID: 37020359 DOI: 10.1002/btpr.3343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 03/20/2023] [Accepted: 03/22/2023] [Indexed: 04/07/2023]
Abstract
Host-cell proteins (HCPs) and high molecular weight (HMW) species have historically been treated as independent classes of impurities in the downstream processing of monoclonal antibodies (mAbs), but recent indications suggest that they may be partially linked. We have explored this connection with a shotgun proteomic analysis of HMW impurities that were isolated from harvest cell culture fluid (HCCF) and protein A eluate using size-exclusion chromatography (SEC). As part of the proteomic analysis, a cross-digest study was performed in which samples were analyzed using both the standard and native digest techniques to enable a fair comparison between bioprocess pools. This comparison reveals that the HCP profiles of HCCF and protein A eluate overlap substantially more than previous work has suggested, because hundreds of HCPs are conserved in aggregates that may be up to ~50 nm in hydrodynamic radius and that persist through the protein A capture step. Quantitative SWATH proteomics suggests that the majority of the protein A eluate's HCP mass is found in such aggregates, and this is corroborated by ELISA measurements on SEC fractions. The SWATH data also show that intra-aggregate concentrations of individual HCPs are positively correlated between aggregates that were isolated from HCCF and protein A eluate, and species that have generally been considered difficult to remove tend to be more concentrated than their counterparts. These observations support prior hypotheses regarding aggregate-mediated HCP persistence through protein A chromatography and highlight the importance of this persistence mechanism.
Collapse
Affiliation(s)
- Chase E Herman
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, 19716, USA
| | - Lie Min
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, 19716, USA
| | - Leila H Choe
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, 19716, USA
| | - Ronald W Maurer
- Biologics Process Development, Bristol Myers Squibb, Massachusetts, 01434, Devens, USA
| | - Xuankuo Xu
- Biologics Process Development, Bristol Myers Squibb, Massachusetts, 01434, Devens, USA
| | - Sanchayita Ghose
- Biologics Process Development, Bristol Myers Squibb, Massachusetts, 01434, Devens, USA
| | - Kelvin H Lee
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, 19716, USA
| | - Abraham M Lenhoff
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware, 19716, USA
| |
Collapse
|
2
|
Herman CE, Min L, Choe LH, Maurer RW, Xu X, Ghose S, Lee KH, Lenhoff AM. Behavior of host-cell-protein-rich aggregates in antibody capture and polishing chromatography. J Chromatogr A 2023; 1702:464081. [PMID: 37244165 DOI: 10.1016/j.chroma.2023.464081] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 05/15/2023] [Accepted: 05/16/2023] [Indexed: 05/29/2023]
Abstract
Recent work has shown that aggregates in monoclonal antibody (mAb) solutions may be made up not just of mAb oligomers but can also harbor hundreds of host-cell proteins (HCPs), suggesting that aggregate persistence through downstream purification operations may be related to HCP clearance. We have examined this in a primary analysis of aggregate persistence through processing steps that are typically implemented for HCP reduction, demonstrating that the phenomenon is relevant to depth filtration, protein A chromatography and flow-through anion-exchange (AEX) polishing. Confocal laser scanning microscopy observations show that aggregates compete with the mAb to adsorb specifically in protein A chromatography and that this competitive interaction is integral to the efficacy of protein A washes. Column chromatography reveals that the protein A elution tail can have a relatively high concentration of aggregates, which corroborates analogous observations from recent HCP studies. Similar measurements in flow-through AEX chromatography show that relatively large aggregates that harbor HCPs and that persist into the protein A eluate can be retained to an extent that appears to depend primarily on the resin surface chemistry. The total aggregate mass fraction of both protein A eluate pools (∼ 2.4 - 3.6%) and AEX flow-through fractions (∼ 1.5 - 3.2%) correlates generally with HCP concentrations measured using enzyme-linked immunosorbent assay (ELISA) as well as the number of HCPs that may be identified in proteomic analysis. This suggests that quantification of the aggregate mass fraction may serve as a convenient albeit imperfect surrogate for informing early process development decisions regarding HCP clearance strategies.
Collapse
Affiliation(s)
- Chase E Herman
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | - Lie Min
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | - Leila H Choe
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | - Ronald W Maurer
- Biologics Development, Bristol Myers Squibb, Devens, MA 01434, USA
| | - Xuankuo Xu
- Biologics Development, Bristol Myers Squibb, Devens, MA 01434, USA
| | - Sanchayita Ghose
- Biologics Development, Bristol Myers Squibb, Devens, MA 01434, USA
| | - Kelvin H Lee
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | - Abraham M Lenhoff
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
| |
Collapse
|
3
|
Bhoyar S, Foster M, Oh YH, Xu X, Traylor SJ, Guo J, Ghose S, Lenhoff AM. Engineering protein A ligands to mitigate antibody loss during high-pH washes in protein A chromatography. J Chromatogr A 2023; 1696:463962. [PMID: 37043977 DOI: 10.1016/j.chroma.2023.463962] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 03/30/2023] [Accepted: 04/01/2023] [Indexed: 04/05/2023]
Abstract
Protein A chromatography is a workhorse in monoclonal antibody (mAb) manufacture since it provides effective separation of mAbs from impurities such as host-cell proteins (HCPs) in a single capture step. HCP clearance can be aided by the inclusion of a wash step prior to low-pH elution. Although high-pH washes can be effective in removing additional HCPs from the loaded column, they may also contribute to a reduced mAb yield. In this work we show that this yield loss is reflected in a pH-dependent variation of the equilibrium binding capacity of the protein A resin, which is also observed for the capacity of the Fc fragments alone and therefore not a result of steric interactions involving the Fab fragments in the intact mAbs. We therefore hypothesized that the high-pH wash loss was due to protonation or deprotonation of ionizable residues on the protein A ligand. To evaluate this, we applied a rational protein engineering approach to the Z domain (the Fc-binding component of most commercial protein A ligands) and expressed engineered mutants in E. coli. Biolayer interferometry and affinity chromatography experiments showed that some of the Z domain mutants were able to mitigate wash loss at high pH while maintaining similar binding characteristics at neutral pH. These experiments enabled elucidation of the roles of specific interactions in the Z domain - Fc complex, but more importantly offer a route to ameliorating the disadvantages of high-pH washes in protein A chromatography.
Collapse
|
4
|
Chu LK, Borujeni EE, Xu X, Ghose S, Zydney AL. Comparison of host cell protein removal by depth filters with diatomaceous earth and synthetic silica filter aids using model proteins. Biotechnol Bioeng 2023. [PMID: 36929487 DOI: 10.1002/bit.28386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 02/24/2023] [Accepted: 03/15/2023] [Indexed: 03/18/2023]
Abstract
A number of studies have demonstrated that depth filtration can provide significant adsorptive removal of host cell proteins (HCP), but there is still considerable uncertainty regarding the underlying factors controlling HCP binding. This study compared the binding characteristics of two fine grade depth filters, the X0SP (polyacrylic fiber with a synthetic silica filter aid) and X0HC (cellulose fibers with diatomaceous earth as a filter aid), using a series of model proteins with well-defined physical characteristics. Protein binding to the X0SP filter was dominated by electrostatic interactions with greatest capacity for positively-charged proteins. In contrast, the X0HC filter showed greater binding of more hydrophobic proteins although electrostatic interactions also played a role. In addition, ovotransferrin showed unusually high binding capacity to the X0HC, likely due to interactions with metals in the diatomaceous earth. Scanning electron microscopy with energy dispersive spectroscopy was used to obtain additional understanding of the binding behavior. These results provide important insights into the physical phenomena governing HCP binding to both fully synthetic and natural (cellulose + diatomaceous earth) depth filters. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Liang-Kai Chu
- Department of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802
| | - Ehsan Espah Borujeni
- Bristol Myers Squibb, Biologics Process Development, Global Product Development and Supply, Devens, MA, 01434
| | - Xuankuo Xu
- Bristol Myers Squibb, Biologics Process Development, Global Product Development and Supply, Devens, MA, 01434
| | - Sanchayita Ghose
- Bristol Myers Squibb, Biologics Process Development, Global Product Development and Supply, Devens, MA, 01434
| | - Andrew L Zydney
- Department of Chemical Engineering, The Pennsylvania State University, University Park, PA, 16802
| |
Collapse
|
5
|
Kim TK, Bham AA, Fioretti I, Angelo J, Xu X, Ghose S, Morbidelli M, Sponchioni M. Role of the gradient slope during the product internal recycling for the multicolumn countercurrent solvent gradient purification of PEGylated proteins. J Chromatogr A 2023; 1692:463868. [PMID: 36803771 DOI: 10.1016/j.chroma.2023.463868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 02/06/2023] [Accepted: 02/08/2023] [Indexed: 02/11/2023]
Abstract
Protein PEGylation, i.e. functionalization with poly(ethylene glycol) chains, has been demonstrated an efficient way to improve the therapeutic index of these biopharmaceuticals. We demonstrated that Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) is an efficient process for the separation of PEGylated proteins (Kim et al., Ind. and Eng. Chem. Res. 2021, 60, 29, 10764-10776), thanks to the internal recycling of product-containing side fractions. This recycling phase plays a critical role in the economy of MCSGP as it avoids wasting valuable product, but at the same time impacts its productivity extending the overall process duration. In this study, our aim is to elucidate the role of the gradient slope within this recycling stage on the yield and productivity of MCSGP for two case-studies: PEGylated lysozyme and an industrially relevant PEGylated protein. While all the examples of MCSGP in the literature refer to a single gradient slope in the elution phase, for the first time we systematically investigate three different gradient configurations: i) a single gradient slope throughout the entire elution, ii) recycling with an increased gradient slope, to shed light on the competition between volume of the recycled fraction and required inline dilution and iii) an isocratic elution during the recycling phase. The dual gradient elution proved to be a valuable solution for boosting the recovery of high-value products, with the potential for alleviating the pressure on the upstream processing.
Collapse
Affiliation(s)
- Tae Keun Kim
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7 20131 Milano, Italy
| | - Abdallah Ayub Bham
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7 20131 Milano, Italy
| | - Ismaele Fioretti
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7 20131 Milano, Italy
| | - James Angelo
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Inc., Devens, MA, 01434, USA
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Inc., Devens, MA, 01434, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Inc., Devens, MA, 01434, USA
| | - Massimo Morbidelli
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7 20131 Milano, Italy
| | - Mattia Sponchioni
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7 20131 Milano, Italy.
| |
Collapse
|
6
|
Mitra J, Bhushan C, Ghose S, Mills D, Chan H, Tarasek M, Foo T, Wells S, Jupitz S, Bednarz B, Brace C, Holmes J, Yeo D. Abstract No. 49 Motion Compensation in 3D MRI-US Fusion Using Fast Deformable Registration: A Feasibility Study for Real-Time Intervention. J Vasc Interv Radiol 2023. [DOI: 10.1016/j.jvir.2022.12.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
7
|
Furcht C, VanSeveren M, Holstein M, Feroz H, Ghose S. Use of Monte Carlo simulations for improved facility fit planning in downstream biomanufacturing and technology transfer. Biotechnol Prog 2023; 39:e3306. [PMID: 36264017 DOI: 10.1002/btpr.3306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 10/05/2022] [Accepted: 10/17/2022] [Indexed: 11/10/2022]
Abstract
Biologics manufacturing is capital and consumable intensive with need for advanced inventory planning to account for supply chain constraints. Early-stage process design and technology transfer are often challenging due to limited information on process variability regarding bioreactor titer, process yield, and product quality. Monte Carlo (MC) methods offer a stochastic modeling approach for process optimization where probabilities of occurrence for process inputs are incorporated into a deterministic model to simulate more likely scenarios for process outputs. In this study, we explore MC simulation-based design of a monoclonal antibody downstream manufacturing process. We demonstrate that this probabilistic approach offers more representative outcomes over the conventional worst-case approach where the theoretical minimum and maximum values of each process parameter are used without consideration for their probability of occurrence. Our work demonstrates case studies on more practically sizing unit operations to improve consumable utilization, thereby reducing manufacturing costs. We also used MC simulations to minimize process cadence by constraining the number of cycles per unit operation to fit facility preferences. By factoring in process uncertainty, we have implemented MC simulation-based facility fit analyses to efficiently plan for inventory when accounting for process constraints during technology transfer from lab-scale to clinical or commercial manufacturing.
Collapse
Affiliation(s)
- Christopher Furcht
- Biologics Process Development, Bristol Myers Squibb Company, Summit, New Jersey, USA
| | - Michael VanSeveren
- Biologics Process Development, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Melissa Holstein
- Biologics Process Development, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Hasin Feroz
- Biologics Process Development, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Process Development, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| |
Collapse
|
8
|
Waller JA, Zheng J, Dyer R, Slaney T, Wu W, Tao L, Ghose S. Ceramic hydroxyapatite chromatography plays a critical role in bispecific antibody purification process for impurity removal. Antib Ther 2023; 6:30-37. [PMID: 36683764 PMCID: PMC9847337 DOI: 10.1093/abt/tbac030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 10/31/2022] [Accepted: 11/05/2022] [Indexed: 11/20/2022] Open
Abstract
Background Significant challenges exist in downstream purification of bispecific antibodies (BsAbs) due to the complexity of BsAb architecture. A unique panel of mispaired species can result in a higher level of product-related impurities. In addition to process-related impurities such as host cell proteins (HCPs) and residual DNA (resDNA), these product-related impurities must be separated from the targeted BsAb product to achieve high purity. Therefore, development of an efficient and robust chromatography purification process is essential to ensure the safety, quality, purity and efficacy of BsAb products that consequently meet regulatory requirements for clinical trials and commercialization. Methods We have developed a robust downstream BsAb process consisting of a mixed-mode ceramic hydroxyapatite (CHT) chromatography step, which offers unique separation capabilities tailored to BsAbs, and assessed impurity clearance. Results We demonstrate that the CHT chromatography column provides additional clearance of low molecular weight (LMW) and high molecular weight (HMW) species that cannot be separated by other chromatography columns such as ion exchange for a particular BsAb, resulting in ≥98% CE-SDS (non-reduced) purity. Moreover, through Polysorbate-80 (PS-80) spiking and LC-MS HCP assessments, we reveal complete clearance of potential PS-80-degrading HCP populations in the CHT eluate product pool. Conclusions In summary, these results demonstrate that CHT mixed-mode chromatography plays an important role in separation of product- and process-related impurities in the BsAb downstream process.
Collapse
Affiliation(s)
- Jessica A Waller
- Biologics Development, Bristol Myers Squibb, Summit, NJ 07901 USA
| | - Ji Zheng
- Biologics Development, Bristol Myers Squibb, Summit, NJ 07901 USA
| | - Rachel Dyer
- Biologics Development, Bristol Myers Squibb, Devens, MA 01434 USA
| | - Thomas Slaney
- Biologics Development, Bristol Myers Squibb, New Brunswick, NJ 08901 USA
| | - Wei Wu
- Biologics Development, Bristol Myers Squibb, New Brunswick, NJ 08901 USA
| | - Li Tao
- Biologics Development, Bristol Myers Squibb, New Brunswick, NJ 08901 USA
| | - Sanchayita Ghose
- Biologics Development, Bristol Myers Squibb, Devens, MA 01434 USA
| |
Collapse
|
9
|
Kim TK, Sechi B, Romero Conde JJ, Angelo J, Xu X, Ghose S, Morbidelli M, Sponchioni M. Design and economic investigation of a Multicolumn Countercurrent Solvent Gradient Purification unit for the separation of an industrially relevant PEGylated protein. J Chromatogr A 2022; 1681:463487. [PMID: 36115185 DOI: 10.1016/j.chroma.2022.463487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 08/31/2022] [Accepted: 09/05/2022] [Indexed: 10/14/2022]
Abstract
Conjugation of biopharmaceuticals to polyethylene glycol chains, known as PEGylation, is nowadays an efficient and widely exploited strategy to improve critical properties of the active molecule, including stability, biodistribution profile, and reduced clearance. A crucial step in the manufacturing of PEGylated drugs is the purification. The reference process in industrial settings is single-column chromatography, which can meet the stringent purity requisites only at the expenses of poor product recoveries. A valuable solution to this trade-off is the Multicolumn Countercurrent Solvent Gradient Purification (MCSGP), which allows the internal and automated recycling of product-containing side fractions that are typically discarded in the batch processes. In this study, an ad hoc design procedure was applied to the single-column batch purification of an industrially relevant PEGylated protein, with the aim of defining optimal collection window, elution duration and elution buffer ionic strength to be then transferred to the MCSGP. This significantly alleviates the design of the continuous operation, subjected to manifold process parameters. The MCSGP designed by directly transferring the optimal parameters allowed to improve the yield and productivity by 8.2% and 17.8%, respectively, when compared to the corresponding optimized batch process, ensuring a purity specification of 98.0%. Once the efficacy of MCSGP was demonstrated, a detailed analysis of its cost of goods was performed and compared to the case of single-column purification. To the best of our knowledge, this is the first example of a detailed economic investigation of the MCSGP across different manufacturing scenarios and process cadences of industrial relevance, which demonstrated not only the viability of this continuous technology but also its flexibility.
Collapse
Affiliation(s)
- Tae Keun Kim
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7, Milano 20131, Italy
| | - Benedetta Sechi
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7, Milano 20131, Italy
| | - Juan Jose Romero Conde
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb Inc., Devens, MA 01434, USA
| | - James Angelo
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb Inc., Devens, MA 01434, USA
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb Inc., Devens, MA 01434, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb Inc., Devens, MA 01434, USA
| | - Massimo Morbidelli
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7, Milano 20131, Italy
| | - Mattia Sponchioni
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7, Milano 20131, Italy.
| |
Collapse
|
10
|
Borujeni EE, Jin W, Shao C, Chennamsetty N, Xu X, Ghose S. Role of harvest depth filtration in controlling product-related impurities for a bispecific antibody. Antib Ther 2022; 5:268-279. [PMID: 36299416 PMCID: PMC9590317 DOI: 10.1093/abt/tbac023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Revised: 08/29/2022] [Accepted: 09/21/2022] [Indexed: 11/25/2022] Open
Abstract
Background Bispecific antibodies (BsAb) belong to a novel antibody category with advantages over traditional mono-specific therapeutic antibodies. However, product variants are also commonly seen during the production of BsAb, which poses significant challenges to downstream processing. In this study, the adsorptive characteristics of a BsAb product and its variants were investigated for a set of depth filters during primary recovery of the cell culture fluid. Methods The retention of the BsAb product and its variants on a set of Millistak+® D0HC and X0HC depth filters were first investigated, followed by studying the mechanism of their adsorption on the depth filters. The chemical and structural properties of depth filters along with the molecular properties of the product and its variants were studied subsequently. Results The X0HC filter was found to be able to retain a significant amount of low molecular weight (LMW) variants along with a low amount of main product retained. Different levels of retention, observed for these variants, were correlated to their different hydrophobic and charge characteristics in relation with the adsorptive properties of the depth filters used. Electrostatic, hydrophobic, and hydrogen bonding interactions were found to be the key forces to keep product variants retained on the depth filter where the higher hydrophobicity of the LMW variants may cause them to be preferentially retained. Conclusion Harvest depth filters potentially can be utilized for retaining the BsAb variants, which depends on relative molecular properties of the product and its variants and adsorptive properties of the depth filters used.
Collapse
Affiliation(s)
- Ehsan Espah Borujeni
- Biologics Downstream Process Development , , Devens, United States
- Bristol Myers Squibb , , Devens, United States
| | - Weixin Jin
- Biologics Downstream Process Development , , Devens, United States
- Bristol Myers Squibb , , Devens, United States
| | - Chun Shao
- Global Process Analytical Science , , Devens, United States
- Bristol Myers Squibb , , Devens, United States
| | - Naresh Chennamsetty
- Analytical Development and Attribute Sciences , , New Brunswick, United States
- Bristol Myers Squibb , , New Brunswick, United States
| | - Xuankuo Xu
- Biologics Downstream Process Development , , Devens, United States
- Bristol Myers Squibb , , Devens, United States
| | - Sanchayita Ghose
- Biologics Downstream Process Development , , Devens, United States
- Bristol Myers Squibb , , Devens, United States
| |
Collapse
|
11
|
Feroz H, Chennamsetty N, Byers S, Holstein M, Li ZJ, Ghose S. Assessing detergent-mediated virus inactivation, protein stability, and impurity clearance in biologics downstream processes. Biotechnol Bioeng 2022; 119:1091-1104. [PMID: 35023152 DOI: 10.1002/bit.28034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 12/13/2021] [Accepted: 01/04/2022] [Indexed: 11/12/2022]
Abstract
Detergent-mediated virus inactivation (VI) provides a valuable orthogonal strategy for viral clearance in mammalian processes, in particular for next-generation continuous manufacturing. Furthermore, there exists an industry-wide need to replace the conventionally employed detergent Triton X-100 with eco-friendly alternatives. However, given Triton X-100 has been the gold standard for VI due its minimal impact on protein stability and high inactivation efficacy, inactivation by other eco-friendly detergents and its impact on protein stability is not well understood. In this study, the sugar-based detergent commonly used in membrane protein purification, n-dodecyl-β- d-maltoside was found to be a promising alternative for VI. We investigated a panel of detergents to compare the relative VI efficacy, impact on therapeutic quality attributes, and clearance of the VI agent and other impurities through subsequent chromatographic steps. Detergent-mediated inactivation and protein stability showed comparable trends to low pH inactivation. Using experimental and modeling data, we found detergent-mediated product aggregation and its kinetics to be driven by extrinsic factors such as detergent and protein concentration. Detergent-mediated aggregation was also impacted by an initial aggregation level as well as intrinsic factors such as the protein sequence and detergent hydrophobicity, and critical micelle concentration. Knowledge gained here on factors driving product stability and VI provides valuable insight to design, standardize, and optimize conditions (concentration and duration of inactivation) for screening of detergent-mediated VI.
Collapse
Affiliation(s)
- Hasin Feroz
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Co., Devens, Massachusetts, USA
| | - Naresh Chennamsetty
- Analytical Development and Attribute Sciences, Biologics Development, Bristol Myers Squibb Company, New Brunswick, New Jersey, USA
| | - Sara Byers
- Analytical Development and Attribute Sciences, Biologics Development, Bristol Myers Squibb Co., Devens, Massachusetts, USA
| | - Melissa Holstein
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Co., Devens, Massachusetts, USA
| | - Zheng J Li
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Co., Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Co., Devens, Massachusetts, USA
| |
Collapse
|
12
|
Billups M, Minervini M, Holstein M, Feroz H, Ranjan S, Hung J, Bao H, Li ZJ, Ghose S, Zydney AL. Role of membrane structure on the filtrate flux during monoclonal antibody filtration through virus retentive membranes. Biotechnol Prog 2022; 38:e3231. [PMID: 34994527 DOI: 10.1002/btpr.3231] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 12/15/2021] [Accepted: 01/02/2022] [Indexed: 02/02/2023]
Abstract
Virus removal filtration is a critical step in the manufacture of monoclonal antibody products, providing a robust size-based removal of both enveloped and non-enveloped viruses. Many monoclonal antibodies show very large reductions in filtrate flux during virus filtration, with the mechanisms governing this behavior and its dependence on the properties of the virus filter and antibody remaining largely unknown. Experiments were performed using the highly asymmetric Viresolve® Pro and the relatively homogeneous Pegasus™ SV4 virus filters using a highly purified monoclonal antibody. The filtrate flux for a 4 g/L antibody solution through the Viresolve® Pro decreased by about 10-fold when the filter was oriented with the skin side down but by more than 1000-fold when the asymmetric filter orientation was reversed and used with the skin side up. The very large flux decline observed with the skin side up could be eliminated by placing a large pore size prefilter directly on top of the virus filter; this improvement in filtrate flux was not seen when the prefilter was used inline or as a batch prefiltration step. The increase in flux due to the prefilter was not related to the removal of large protein aggregates or to an alteration in the extent of concentration polarization. Instead, the prefilter appears to transiently disrupt reversible associations of the antibodies caused by strong intermolecular attractions. These results provide important insights into the role of membrane morphology and antibody properties on the filtrate flux during virus filtration.
Collapse
Affiliation(s)
- Matthew Billups
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA
| | - Mirko Minervini
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA
| | - Melissa Holstein
- Bristol Myers Squibb Biologics Process Development, Global Product Development and Supply, Devens, Massachusetts, USA
| | - Hasin Feroz
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA.,Bristol Myers Squibb Biologics Process Development, Global Product Development and Supply, Devens, Massachusetts, USA
| | - Swarnim Ranjan
- Bristol Myers Squibb Biologics Process Development, Global Product Development and Supply, Devens, Massachusetts, USA
| | - Jessica Hung
- Bristol Myers Squibb Biologics Process Development, Global Product Development and Supply, Devens, Massachusetts, USA
| | - Haiying Bao
- Bristol Myers Squibb Biologics Process Development, Global Product Development and Supply, Devens, Massachusetts, USA
| | - Zheng Jian Li
- Bristol Myers Squibb Biologics Process Development, Global Product Development and Supply, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Bristol Myers Squibb Biologics Process Development, Global Product Development and Supply, Devens, Massachusetts, USA
| | - Andrew L Zydney
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA
| |
Collapse
|
13
|
Herman CE, Xu X, Traylor SJ, Ghose S, Li ZJ, Lenhoff AM. Behavior of weakly adsorbing protein impurities in flow-through ion-exchange chromatography. J Chromatogr A 2021; 1664:462788. [PMID: 34998025 DOI: 10.1016/j.chroma.2021.462788] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 12/23/2021] [Accepted: 12/23/2021] [Indexed: 10/19/2022]
Abstract
Flow-through ion-exchange chromatography is frequently used in polishing biotherapeutics, but the factors that contribute to impurity persistence are incompletely understood. A large number of dilute impurities may be encountered that exhibit physicochemical diversity, making the flow-through separation performance highly sensitive to process conditions. The analysis presented in this work develops two novel correlations that offer transferable insights into the chromatographic behavior of weakly adsorbing impurities. The first, based on column simulations and validated experimentally, delineates the relative contributions of thermodynamic, transport, and geometric properties in dictating the initial breakthrough volumes of dilute species. The Graetz number for mass transfer was found to generalize the transport contributions, enabling estimation of a threshold in the equilibrium constant below which impurity persistence is expected. Impurity adsorption equilibria are needed to use this correlation, but such data are not typically available. The second relationship presented in this work may be used to reduce the experimental burden of estimating adsorption equilibria as a function of ionic strength. A correlation between stoichiometric displacement model parameters was found by consolidating isocratic retention data for over 200 protein-pH-resin combinations from the extant literature. Coupled with Yamamoto's analysis of linear gradient elution data, this correlation may be used to estimate retentivity approximately from a single experimental measurement, which could prove useful in predicting host-cell protein chromatographic behavior.
Collapse
Affiliation(s)
- Chase E Herman
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | - Xuankuo Xu
- Biologics Process Development, Bristol Myers Squibb, Devens, MA 01434, USA
| | - Steven J Traylor
- Biologics Process Development, Bristol Myers Squibb, Devens, MA 01434, USA
| | - Sanchayita Ghose
- Biologics Process Development, Bristol Myers Squibb, Devens, MA 01434, USA
| | - Zheng Jian Li
- Biologics Process Development, Bristol Myers Squibb, Devens, MA 01434, USA
| | - Abraham M Lenhoff
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA.
| |
Collapse
|
14
|
Joshi PU, Meingast CL, Xu X, Holstein M, Feroz H, Ranjan S, Ghose S, Li ZJ, Heldt CL. Virus inactivation at moderately low pH varies with virus and buffer properties. Biotechnol J 2021; 17:e2100320. [PMID: 34874097 DOI: 10.1002/biot.202100320] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2021] [Revised: 11/23/2021] [Accepted: 11/29/2021] [Indexed: 11/12/2022]
Abstract
BACKGROUND Virus inactivation is a critical operation in therapeutic protein manufacturing. Low pH buffers are a widely used strategy to ensure robust enveloped virus clearance. However, the choice of model virus can give varying results in viral clearance studies. Pseudorabies virus (SuHV) or herpes simplex virus-1 (HSV-1) are frequently chosen as model viruses to demonstrate the inactivation for the herpes family. RESULTS In this study, SuHV, HSV-1, and equine arteritis virus (EAV) were used to compare the inactivation susceptibility at pH 4.0 and 4°C. SuHV and HSV-1 are from the same family, and EAV was chosen as a small, enveloped virus. Glycine, acetate, and citrate buffers at pH 4.0 and varying buffer strengths were studied. The inactivation susceptibility was found to be in the order of SuHV > HSV > EAV. The buffer effectiveness was found to be in the order of citrate > acetate > glycine. The smaller virus, EAV, remained stable and infectious in all the buffer types and compositions studied. CONCLUSION The variation in inactivation susceptibility of herpes viruses indicated that SuHV and HSV cannot be interchangeably used as a virus model for inactivation studies. Smaller viruses might remain adventitiously infective at moderately low pH.
Collapse
Affiliation(s)
- Pratik U Joshi
- Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA.,Health Research Institute, Michigan Technological University, Houghton, Michigan, USA
| | - Christa L Meingast
- Health Research Institute, Michigan Technological University, Houghton, Michigan, USA.,Department of Environmental Engineering, Michigan Technological University, Houghton, Michigan, USA
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Melissa Holstein
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Hasin Feroz
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Swarnim Ranjan
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Caryn L Heldt
- Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA.,Health Research Institute, Michigan Technological University, Houghton, Michigan, USA
| |
Collapse
|
15
|
Feroz H, Cetnar D, Hewlett R, Sharma S, Holstein M, Ghose S, Li ZJ. Surrogate model to screen for inactivation-based clearance of enveloped viruses during biotherapeutics process development. Biotechnol J 2021; 16:e2100176. [PMID: 34506679 DOI: 10.1002/biot.202100176] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 09/03/2021] [Accepted: 09/07/2021] [Indexed: 11/07/2022]
Abstract
Viral surrogates to screen for virus inactivation (VI) can be a faster, cheaper and safer alternative to third-party testing of pathogenic BSL2 (Biosafety level 2) model viruses. Although the bacteriophage surrogate, Ø6, has been used to assess low pH BSL2 VI, it has not been used for evaluation of detergent-mediated VI. Furthermore, Ø6 is typically assayed through host cell infectivity which introduces the risk of cross-contaminating other cell lines in the facility. To circumvent contamination, we developed an in-house RT-qPCR (Reverse transcriptase quantitative polymerase chain reaction) assay for selective detection of active Ø6 from a population of live and dead phage. The RT-qPCR assay was used to evaluate Ø6 inactivation in cell culture fluid of monoclonal antibody and fusion protein. Complementary Ø6 infectivity was also conducted at a third-party testing facility. The Ø6 RT-qPCR and infectivity data was modeled against VI of three BSL2 viruses, X- MuLV, A- MuLV and HSV-1 in corresponding therapeutics. Both Ø6 methods demonstrate that any VI agent showing Ø6 clearance of a minimum of 2.5 logs would demonstrate complete BSL2 VI of ≥ 4.0 logs. Compared to BSL2 virus testing, this in-house Ø6 RT-qPCR tool can screen VI agents at 5% the cost and a turnaround time of 2 to 3 days vs. 4 to 7 months.
Collapse
Affiliation(s)
- Hasin Feroz
- Biologics Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Daniel Cetnar
- Biologics Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Robert Hewlett
- Biologics Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Satish Sharma
- Biologics Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Melissa Holstein
- Biologics Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Zheng Jian Li
- Biologics Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| |
Collapse
|
16
|
Park SY, Egan S, Cura AJ, Aron KL, Xu X, Zheng M, Borys M, Ghose S, Li Z, Lee K. Untargeted proteomics reveals upregulation of stress response pathways during CHO-based monoclonal antibody manufacturing process leading to disulfide bond reduction. MAbs 2021; 13:1963094. [PMID: 34424810 PMCID: PMC8386704 DOI: 10.1080/19420862.2021.1963094] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Monoclonal antibody (mAb) interchain disulfide bond reduction can cause a loss of function and negatively impact the therapeutic’s efficacy and safety. Disulfide bond reduction has been observed at various stages during the manufacturing process, including processing of the harvested material. The factors and mechanisms driving this phenomenon are not fully understood. In this study, we examined the host cell proteome as a potential factor affecting the susceptibility of a mAb to disulfide bond reduction in the harvested cell culture fluid (HCCF). We used untargeted liquid-chromatography-mass spectrometry-based proteomics experiments in conjunction with a semi-automated protein identification workflow to systematically compare Chinese hamster ovary (CHO) cell protein abundances between bioreactor conditions that result in reduction-susceptible and reduction-free HCCF. Although the growth profiles and antibody titers of these two bioreactor conditions were indistinguishable, we observed broad differences in host cell protein (HCP) expression. We found significant differences in the abundance of glycolytic enzymes, key protein reductases, and antioxidant defense enzymes. Multivariate analysis of the proteomics data determined that upregulation of stress-inducible endoplasmic reticulum (ER) and other chaperone proteins is a discriminatory characteristic of reduction-susceptible HCP profiles. Overall, these results suggest that stress response pathways activated during bioreactor culture increase the reduction-susceptibility of HCCF. Consequently, these pathways could be valuable targets for optimizing culture conditions to improve protein quality.
Collapse
Affiliation(s)
- Seo-Young Park
- Department of Chemical and Biological Engineering, Tufts University, Medford, MA, USA.,School of Chemical Engineering, Sungkyunkwan University, Suwon, Republic of Korea
| | - Susan Egan
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, USA
| | - Anthony J Cura
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, USA
| | - Kathryn L Aron
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, USA
| | - Xuankuo Xu
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, USA
| | - Mengyuan Zheng
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, USA
| | - Michael Borys
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, USA
| | - Sanchayita Ghose
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, USA
| | - Zhengjian Li
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, USA
| | - Kyongbum Lee
- Department of Chemical and Biological Engineering, Tufts University, Medford, MA, USA
| |
Collapse
|
17
|
Chen Z, Qian Y, Song Y, Xu X, Tao L, Mussa N, Ghose S, Li ZJ. Design of next-generation therapeutic IgG4 with improved manufacturability and bioanalytical characteristics. MAbs 2021; 12:1829338. [PMID: 33044887 PMCID: PMC7577236 DOI: 10.1080/19420862.2020.1829338] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Manufacturability of immunoglobulin G4 (IgG4) antibodies from the Chemistry, Manufacture, and Controls (CMC) perspective has received little attention during early drug discovery. Despite the success of protein engineering in improving antibody biophysical properties, a clear gap still exists between rational design of IgG4 candidates and their manufacturing suitability. Here, we illustrate that undesirable two-peak elution profiles in cation-exchange chromatography are attributed to the S228P mutation (in IgG4 core-hinge region) intentionally designed to prevent Fab-arm exchange. A new scaffolding platform for engineering IgG4 antibodies amenable to bioprocessing and bioanalysis is proposed by introducing an “IgG1-like” single-point mutation in the hinge or CH1 region of IgG4S228P. This work offers insight into the design, discovery, and development of innovative therapeutic antibodies that are well suited for robust biomanufacturing and quality control.
Collapse
Affiliation(s)
- Zhiqiang Chen
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company , Devens, MA, USA
| | - Yueming Qian
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company , Devens, MA, USA
| | - Yuanli Song
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company , Devens, MA, USA
| | - Xuankuo Xu
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company , Devens, MA, USA
| | - Li Tao
- Biophysical Characterization, Global Product Development and Supply, Bristol Myers Squibb Company , New Brunswick, NJ, USA
| | - Nesredin Mussa
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company , Devens, MA, USA
| | - Sanchayita Ghose
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company , Devens, MA, USA
| | - Zheng Jian Li
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company , Devens, MA, USA
| |
Collapse
|
18
|
Tang P, Tan Z, Ehamparanathan V, Ren T, Hoffman L, Du C, Song Y, Tao L, Lewandowski A, Ghose S, Li ZJ, Liu S. Optimization and kinetic modeling of interchain disulfide bond reoxidation of monoclonal antibodies in bioprocesses. MAbs 2021; 12:1829336. [PMID: 33031716 PMCID: PMC7577745 DOI: 10.1080/19420862.2020.1829336] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Disulfide bonds play a crucial role in folding and structural stabilization of monoclonal antibodies (mAbs). Disulfide bond reduction may happen during the mAb manufacturing process, resulting in low molecular weight species and possible failure to meet product specifications. Although many mitigation strategies have been developed to prevent disulfide reduction, to the best of our knowledge, reforming disulfide bonds from the reduced antibody in manufacturing has not previously been reported. Here, we explored a novel rescue strategy in the downstream process to repair the broken disulfide bonds via in-vitro redox reactions on Protein A resin. Redox conditions including redox pair (cysteine/cystine ratio), pH, temperature, and reaction time were examined to achieve high antibody purity and a high reaction rate. Under the optimal redox condition, >90% reduced antibody could be reoxidized to form an intact antibody on Protein A resin in an hour. In addition, this study showed high flexibility on the range of the intact mAb fraction in the initial reduced mAb sample (the lower limit of intact mAb faction could be 14% based on the data reported in this study). Furthermore, a kinetic model based on elementary oxidative reactions was constructed to help optimize the reoxidation conditions and to predict product purity. Together, the deep understanding of interchain disulfide bond reoxidation, combined with the predictive kinetic model, provided a good foundation to implement a rescue strategy to generate high-purity antibodies with substantial cost savings in manufacturing processes.
Collapse
Affiliation(s)
- Peifeng Tang
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA.,Department of Paper and Bioprocess Engineering, The State University of New York College of Environmental Science and Forestry , Syracuse, NY, USA
| | - Zhijun Tan
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Vivekh Ehamparanathan
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Tingwei Ren
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Laurel Hoffman
- Global Product Development and Supply, Bristol-Myers Squibb Company , Pennington, NJ, USA
| | - Cheng Du
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Yuanli Song
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Li Tao
- Global Product Development and Supply, Bristol-Myers Squibb Company , Pennington, NJ, USA
| | - Angela Lewandowski
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Sanchayita Ghose
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Zheng Jian Li
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Shijie Liu
- Department of Paper and Bioprocess Engineering, The State University of New York College of Environmental Science and Forestry , Syracuse, NY, USA
| |
Collapse
|
19
|
Chen G, Pagano J, Yu D, Ghose S, Li Z, Ghosh R. Fast and high-resolution purification of a PEGylated protein using a z 2 laterally-fed membrane chromatography device. J Chromatogr A 2021; 1652:462375. [PMID: 34256267 DOI: 10.1016/j.chroma.2021.462375] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 06/19/2021] [Accepted: 06/24/2021] [Indexed: 11/28/2022]
Abstract
PEGylated proteins comprise a class of value-added biopharmaceuticals. High-resolution separation techniques are required for the purification of these molecules. In this study, we discuss the application of a newly developed z2 laterally-fed membrane chromatography (or z2LFMC) device for carrying out high-resolution purification of a PEGylated protein drug. The device used in the current study contained a stack of anion exchange (Q) membranes. The membrane bed-height of this z2LFMC device being small, it could be operated at very high flow rates, at relatively low back pressures. The primary goal was to speedily and efficiently separate a mono-PEGylated protein from impurities present in the PEGylation reaction mixture. A resin-based anion exchange column having the same ligand and bed-volume was used as the control device. The purification performance of the z2LFMC device and the control column were compared terms of resolution, recovery and purity. The z2LFMC device outperformed the control column in terms of every metric compared in this study. Higher purity (85.4% as opposed to 77.9%) and higher recovery (28% greater) of the target mono-PEGylated protein were obtained using the z2LFMC device at 20-time higher speed. These results clearly demonstrate that the z2LFMC device could be a faster and more efficient alternative to resin-based columns for purification of biopharmaceuticals.
Collapse
Affiliation(s)
- Guoqiang Chen
- Department of Chemical Engineering, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L7, Canada
| | - John Pagano
- Biologics Process Development, Bristol-Myers Squibb, 3510F-BDB231, 38 Jackson Road, Devens MA 01434, United States
| | - Deqiang Yu
- Biologics Process Development, Bristol-Myers Squibb, 3510F-BDB231, 38 Jackson Road, Devens MA 01434, United States
| | - Sanchayita Ghose
- Biologics Process Development, Bristol-Myers Squibb, 3510F-BDB231, 38 Jackson Road, Devens MA 01434, United States
| | - Zhengjian Li
- Biologics Process Development, Bristol-Myers Squibb, 3510F-BDB231, 38 Jackson Road, Devens MA 01434, United States
| | - Raja Ghosh
- Department of Chemical Engineering, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L7, Canada.
| |
Collapse
|
20
|
Kim TK, Botti C, Angelo J, Xu X, Ghose S, Li ZJ, Morbidelli M, Sponchioni M. Experimental Design of the Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) Unit for the Separation of PEGylated Proteins. Ind Eng Chem Res 2021. [DOI: 10.1021/acs.iecr.1c01345] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Tae Keun Kim
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7, Milano, 20131, Italy
| | - Chiara Botti
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7, Milano, 20131, Italy
| | - James Angelo
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Inc., Devens, Massachusetts 01434, United States
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Inc., Devens, Massachusetts 01434, United States
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Inc., Devens, Massachusetts 01434, United States
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Inc., Devens, Massachusetts 01434, United States
| | - Massimo Morbidelli
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7, Milano, 20131, Italy
| | - Mattia Sponchioni
- Department of Chemistry, Materials and Chemical Engineering, Politecnico di Milano, Via Mancinelli 7, Milano, 20131, Italy
| |
Collapse
|
21
|
Ren T, Tan Z, Ehamparanathan V, Lewandowski A, Ghose S, Li ZJ. Antibody disulfide bond reduction and recovery during biopharmaceutical process development-A review. Biotechnol Bioeng 2021; 118:2829-2844. [PMID: 33844277 DOI: 10.1002/bit.27790] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 04/07/2021] [Accepted: 04/08/2021] [Indexed: 12/29/2022]
Abstract
Antibody disulfide bond reduction has been a challenging issue in monoclonal antibody manufacturing. It could lead to a decrease of product purity and failure to meet the targeted product profile and/or specifications. More importantly, disulfide bond reduction could also impact drug safety and efficacy. Scientists across the industry have been examining the root causes and developing mitigation strategies to address the challenge. In recent years, with the development of high titer mammalian cell culture processes to meet the rapidly growing demand for antibody biopharmaceuticals, disulfide bond reduction has been observed more frequently. Thus, it is necessary to continue evolving the disulfide reduction mitigation strategies and developing novel approaches to maintain high product quality. Additionally, in recent years as more complex molecules (such as bispecific and trispecific antibodies) emerge, the molecular heterogeneity due to incomplete formation of the interchain disulfide bonds becomes a more imperative challenging issue. Given the disulfide reduction challenges that biotech industry is facing, in this review, we provide a comprehensive scientific summary of the root cause analysis of disulfide reduction during process development of antibody therapeutics, mitigation strategies and its potential remediated recovery based on published papers. First, this paper intends to highlight different aspects of the root cause for disulfide reduction. Secondly, to provide a broader understanding of the disulfide bond reduction in downstream process, this paper discusses disulfide bond reduction impact on product stability, associated analytical methods for disulfide bond reduction detection and characterization, process control strategies as well as their manufacturing implementation. In addition, brief perspectives on the development of future mitigation strategies are also reviewed, including platform alignment, mitigation strategy application for the emerging new modalities such as bispecific and trispecific antibodies as well as using machine learning to identify molecule susceptibility of disulfide bond reduction. The data in this review are originated from the published papers.
Collapse
Affiliation(s)
- Tingwei Ren
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts
| | - Zhijun Tan
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts
| | - Vivekh Ehamparanathan
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts
| | - Angela Lewandowski
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts
| | - Sanchayita Ghose
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts
| | - Zheng Jian Li
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts
| |
Collapse
|
22
|
Quesada-Masachs H, Faloutsos M, López- Corbetó M, Ghose S, Marsal S, Quesada-Masachs E. POS1322 A DATA SCIENCE EVALUATION OF THE JUVENILE ARTHRITIS MULTIDIMENSIONAL ASSESSMENT REPORT (JAMAR) QUESTIONNAIRE FOR IMPROVING MANAGEMENT OF JIA PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3319] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a questionnaire developed to comprehensively assess Juvenile Idiopathic Arthritis (JIA) patients. Despite being translated into 54 languages, there is still limited literature about it. The length of the questionnaire could have been influencing its clinical practicality.Objectives:The purpose of this study is to answer the following questions:a)“Which are the most informative questions?”;b)“How well do the collected data correlate with other clinical variables?”;c)“Are there discrepancies between the perceptions of patients and parents?”;Methods:We included 71 children with JIA according to ILAR criteria, all of them receiving treatment and we followed them up for a year. JAMAR questionnaires were answered by both children and parents at baseline, 6 and 12 months. Also, a thorough clinical examination was performed in every visit: all the joints were clinically assessed for swelling, tenderness, and limited range of motion, and Juvenile Arthritis Disease Activity Score (JADAS), disease activity state, parents and patients assessment through Visual Analogue Scale (VAS), physician’s VAS, Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP) were recorded. We applied state of the art machine learning methods in order to find the most relevant questions in JAMAR. Additionally, we utilized tensor decomposition to identify relevant patient clusters. Furthermore, we correlated these critical questions with clinical and biological parameters recorded. We have compared the discordance rate between patients vs parents responses in 5 of JAMAR parameters as previously reported [1]. We explored the relation between discordance and demographic and clinical variables.Results:A total of 374 JAMAR questionnaires are analyzed with our Machine Learning algorithms. First, we identify a small group of questions as the most relevant for patients and parents. The identified questions exhibit better correlations with the JADAS scores than the non-relevant ones. Second, 96% of the pairs (child-parent) are discordant for at least one item, but the differences are small and VAS well being is the only score with a statistically significant difference (P < 0.0001). We observe a higher rate of activity in the patients exhibiting discordant evaluations with their parents. In addition, the observation patient-parent agreement in Juvenile Arthritis Functionality Scale (JAFS) is better than Pediatric Rheumatology Quality of Life Scale (PRQL).Conclusion:In this study, we revisited the JAMAR questionnaire by applying modern data mining techniques in a longitudinal dataset. Our results suggest that a small number of questions in the JAMAR questionnaire provide significant information and correlate well with the JADAS scores. We argue that this reduced set of questions could make the data collection easier by trading off the number of questions for frequency and ease of self-reported data collection.References:[1]Vanoni F, et al. The difference of disease perception by juvenile idiopathic arthritis patients and their parents: analysis of the JAMAR questionnaire. Pediatr Rheumatol Online J. 2016;14(1):2.Disclosure of Interests:None declared
Collapse
|
23
|
Meingast CL, Joshi PU, Turpeinen DG, Xu X, Holstein M, Feroz H, Ranjan S, Ghose S, Li ZJ, Heldt CL. Physiochemical properties of enveloped viruses and arginine dictate inactivation. Biotechnol J 2021; 16:e2000342. [PMID: 33877739 DOI: 10.1002/biot.202000342] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 03/28/2021] [Accepted: 03/30/2021] [Indexed: 11/06/2022]
Abstract
BACKGROUND Therapeutic protein manufacturing would benefit by having an arsenal of ways to inactivate viruses. There have been many publications on the virus inactivation ability of arginine at pH 4.0, but the mechanism of this inactivation is unknown. This study explored how virus structure and solution conditions enhance virus inactivation by arginine and leads to a better understanding of the mechanism of virus inactivation by arginine. RESULTS Large diameter viruses from the Herpesviridae family (SuHV-1, HSV-1) with loosely packed lipids were highly inactivated by arginine, whereas small diameter, enveloped viruses (equine arteritis virus (EAV) and bovine viral diarrhea virus (BVDV)) with tightly packed lipids were negligibly inactivated by arginine. To increase the inactivation of viruses resistant to arginine, arginine-derivatives and arginine peptides were tested. Derivates and peptides demonstrated that a greater capacity for clustering and added hydrophobicity enhanced virus inactivation. Dynamic light scattering (DLS) and transmission electron microscopy (TEM) detected increases in virus size after arginine exposure, supporting the mechanism of lipid expansion. CONCLUSIONS Arginine most likely interacts with the lipid membrane to cause inactivation. This is shown by larger viruses being more sensitive to inactivation and expansion of the viral size. The enhancement of arginine inactivation when increased hydrophobic molecules are present or arginine is clustered demonstrates a potential mechanism of how arginine interacts with the lipid membrane.
Collapse
Affiliation(s)
- Christa L Meingast
- Department of Environmental Engineering, Michigan Technological University, Houghton, Michigan, USA.,Health Research Institute, Michigan Technological University, Houghton, Michigan, USA
| | - Pratik U Joshi
- Health Research Institute, Michigan Technological University, Houghton, Michigan, USA.,Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
| | - Dylan G Turpeinen
- Health Research Institute, Michigan Technological University, Houghton, Michigan, USA.,Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Melissa Holstein
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Hasin Feroz
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Swarnim Ranjan
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Caryn L Heldt
- Health Research Institute, Michigan Technological University, Houghton, Michigan, USA.,Department of Chemical Engineering, Michigan Technological University, Houghton, Michigan, USA
| |
Collapse
|
24
|
West JM, Feroz H, Xu X, Puri N, Holstein M, Ghose S, Ding J, Li ZJ. Process analytical technology for on-line monitoring of quality attributes during single-use ultrafiltration/diafiltration. Biotechnol Bioeng 2021; 118:2293-2300. [PMID: 33666234 DOI: 10.1002/bit.27741] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 02/03/2021] [Accepted: 02/22/2021] [Indexed: 12/18/2022]
Abstract
Process analytical technology (PAT) is a fast-growing field within bioprocessing that enables innovation in biological drug manufacturing. This study demonstrates novel PAT methods for monitoring multiple quality attributes simultaneously during the ultrafiltration and diafiltration (UF/DF) process operation, the final step of monoclonal antibody (mAb) purification. Size exclusion chromatography (SEC) methods were developed to measure excipients arginine, histidine, and high molecular weight (HMW) species using a liquid chromatography (LC) system with autosampler for both on-line and at-line PAT modes. The methods were applied in UF/DF studies for the comparison of single-use tangential flow filtration (TFF) cassettes to standard reusable cassettes to achieve very high concentration mAb drug substance (DS) in the order of 100-200 g/L. These case studies demonstrated that single-use TFF cassettes are a functionally equivalent, low-cost alternative to standard reusable cassettes, and that the on-line PAT measurement of purity and excipient concentration was comparable to orthogonal offline methods. These PAT applications using an on-line LC system equipped with onboard sample dilution can become a platform system for monitoring of multiple attributes over a wide dynamic range, a potentially valuable tool for biological drug development and manufacturing.
Collapse
Affiliation(s)
- Jay M West
- Biologics Process Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Hasin Feroz
- Biologics Process Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Xia Xu
- Biologics Process Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Neha Puri
- Biologics Process Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Melissa Holstein
- Biologics Process Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Process Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Julia Ding
- Biologics Process Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| | - Z J Li
- Biologics Process Development, Bristol Myers Squibb, Devens, Massachusetts, USA
| |
Collapse
|
25
|
Bigelow E, Song Y, Chen J, Holstein M, Huang Y, Duhamel L, Stone K, Furman R, Li ZJ, Ghose S. Using continuous chromatography methodology to achieve high-productivity and high-purity enrichment of charge variants for analytical characterization. J Chromatogr A 2021; 1643:462008. [PMID: 33780880 DOI: 10.1016/j.chroma.2021.462008] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 01/27/2021] [Accepted: 02/14/2021] [Indexed: 11/28/2022]
Abstract
Charge variants of biological products, such as monoclonal antibodies (mAbs), often play an important role in stability and biological activity. Characterization of these charge variants is challenging, however, primarily due to the lack of both efficient and effective isolation methods. In this work, we present a novel use of an established, high productivity continuous chromatography method, known as multi-column counter-current solvent gradient purification (MCSGP), to create an enriched product that can be better utilized for analytical characterization. We demonstrate the principle of this separation method and compare it to traditional batch HPLC (high performance liquid chromatography) or FPLC (fast protein liquid chromatography) methods, using the isolation of charge variants of different mAbs as a case study. In a majority of cases, we are able to show that the MCSGP method is able to provide enhanced purity and quantity of samples when compared to traditional fractionation methods, using the same separation conditions. In one such case, a sample prepared by MCSGP methodology achieved 95% purity in 10 hours of processing time, while those prepared by FPLC and HPLC achieved purities of 78% and 87% in 48 and 300 hours of processing time, respectively. We further evaluate charge variant enrichment strategies using both salt and pH gradients on cation exchange chromatography (CEX) and anion exchange chromatography (AEX) resins, to provide more effective separation and less sample processing following enrichment. As a result, we find that we are able to utilize different gradients to change the enrichment capabilities of certain charged species. Lastly, we summarize the identified mAb charge variants used in this work, and highlight benefits to analytical characterization of charge variants enriched with the continuous chromatography method. The method adds a new option for charge variant enrichment and facilitates analytical characterization of charge variants.
Collapse
Affiliation(s)
- Elizabeth Bigelow
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA 01434.
| | - Yuanli Song
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA 01434
| | - Jie Chen
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA 01434
| | - Melissa Holstein
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA 01434
| | - Yunping Huang
- Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08901
| | - Lauren Duhamel
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA 01434
| | - Kelly Stone
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA 01434
| | - Ran Furman
- Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08901
| | - Zheng Jian Li
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA 01434
| | - Sanchayita Ghose
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA 01434
| |
Collapse
|
26
|
Xu J, Zheng S, Dawood Z, Hill C, Jin W, Xu X, Ding J, Borys MC, Ghose S, Li ZJ, Pendse G. Productivity improvement and charge variant modulation for intensified cell culture processes by adding a carboxypeptidase B (CpB) treatment step. Biotechnol Bioeng 2021; 118:3334-3347. [PMID: 33624836 DOI: 10.1002/bit.27723] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Revised: 01/11/2021] [Accepted: 02/19/2021] [Indexed: 12/12/2022]
Abstract
The goal of cell culture process intensification is to improve productivity while maintaining acceptable quality attributes. In this report, four processes, namely a conventional manufacturing Process A, and processes intensified by enriched N-1 seed (Process B), by perfusion N-1 seed (Process C), and by perfusion production (Process D) were developed for the production of a monoclonal antibody. The three intensified processes substantially improved productivity, however, the product either failed to meet the specification for charge variant species (main peak) for Process D or the production process required early harvest to meet the specification for charge variant species, Day 10 or Day 6 for Processes B and C, respectively. The lower main peak for the intensified processes was due to higher basic species resulting from higher C-terminal lysine. To resolve this product quality issue, we developed an enzyme treatment method by introducing carboxypeptidase B (CpB) to clip the C-terminal lysine, leading to significantly increased main peak and an acceptable and more homogenous product quality for all the intensified processes. Additionally, Processes B and C with CpB treatment extended bioreactor durations to Day 14 increasing titer by 38% and 108%, respectively. This simple yet effective enzyme treatment strategy could be applicable to other processes that have similar product quality issues.
Collapse
Affiliation(s)
- Jianlin Xu
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Shun Zheng
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Zeinab Dawood
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Charles Hill
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Weixin Jin
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Xuankuo Xu
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Julia Ding
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Michael C Borys
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Zheng Jian Li
- Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Girish Pendse
- Global Product Development and Supply, Bristol Myers Squibb Company, Summit, New Jersey, USA
| |
Collapse
|
27
|
Billups M, Minervini M, Holstein M, Feroz H, Ranjan S, Hung J, Bao H, Ghose S, Li ZJ, Zydney AL. Antibody retention by virus filtration membranes: Polarization and sieving effects. J Memb Sci 2021. [DOI: 10.1016/j.memsci.2020.118884] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Angelo JM, Potter K, Müller-Späth T, Xu X, Li ZJ, Ghose S. Continued insights into virus clearance validation across continuous capture chromatography. Biotechnol Bioeng 2021; 118:3604-3609. [PMID: 33421115 DOI: 10.1002/bit.27674] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 01/04/2021] [Indexed: 11/10/2022]
Abstract
Multi-column capture chromatography (MCC) has gained increased attention lately due to the significant economic and process-related advantages it offers compared to traditional batch mode chromatography. However, for wide adoption of this technology in the clinical and commercial space, it requires scalable models for viral validation. In this study, additional viral validation studies were conducted under cGLP guidelines to assess retro-(X-MuLV) and parvo-virus (minute virus of mice) clearance across twin-column continuous capture chromatography (CaptureSMB) to supplement work previously performed. A surrogate model was validated using standard batch mode chromatography equipment based on flow path modifications to mimic the loading strategy employed in CaptureSMB. In addition, aged resin was used in this surrogate format to assess the impact of resin lifetime on viral clearance during continuous capture operation. The impact of column loading was also explored to shed light on the viral clearance mechanisms of protein A chromatography in overloading conditions. The proposed approach greatly simplifies MCC virus validation studies, and provides a robust strategy for regulatory filing of continuous biomanufacturing processes.
Collapse
Affiliation(s)
- James M Angelo
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Kevin Potter
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | | | - Xuankuo Xu
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Zheng Jian Li
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Development, Global Product Development and Supply, Bristol Myers Squibb Company, Devens, Massachusetts, USA
| |
Collapse
|
29
|
Dyer R, Song Y, Chen J, Bigelow E, McGinnis J, Jenkins L, Ghose S, Li ZJ. Mechanistic insights into viral clearance during the chromatography steps in antibody processes by using virus surrogates. Biotechnol Prog 2021; 36:e3057. [PMID: 33405373 DOI: 10.1002/btpr.3057] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 07/24/2020] [Accepted: 07/27/2020] [Indexed: 11/12/2022]
Abstract
Viral safety is required for biological products to treat human diseases, and the burden of inactivation and or virus removal lies on the downstream purification process. Minute virus of mice (MVM) is a nonenveloped parvovirus commonly used as the worst-case model virus in validation studies because of its small size and high chemical stability. In this study, we investigated the use of MVM-mock virus particle (MVP) and bacteriophage ΦX174 as surrogates for MVM to mimic viral clearance studies, with a focus on chromatography operations. Based on structural models and comparison of log reduction value among MVM, MVP, and ΦX174, it was demonstrated that MVP can be used as a noninfectious surrogate to assess viral clearance during process development in multiple chromatography systems in a biosafety level one (BSL-1) laboratory. Protein A (ProA) chromatography was investigated to strategically assess the impact of the resin, impurities, and the monoclonal antibody product on virus removal.
Collapse
Affiliation(s)
- Rachel Dyer
- Biologics Development, Bristol-Myers Squibb, Devens, Massachusetts, USA
| | - Yuanli Song
- Biologics Development, Bristol-Myers Squibb, Devens, Massachusetts, USA
| | - Jie Chen
- Biologics Development, Bristol-Myers Squibb, Devens, Massachusetts, USA
| | - Elizabeth Bigelow
- Biologics Development, Bristol-Myers Squibb, Devens, Massachusetts, USA
| | - Jennifer McGinnis
- Biologics Development, Bristol-Myers Squibb, Devens, Massachusetts, USA
| | - Lauren Jenkins
- Biologics Development, Bristol-Myers Squibb, Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Development, Bristol-Myers Squibb, Devens, Massachusetts, USA
| | - Zheng Jian Li
- Biologics Development, Bristol-Myers Squibb, Devens, Massachusetts, USA
| |
Collapse
|
30
|
Huang C, Wang Y, Xu X, Mills J, Jin W, Ghose S, Li ZJ. Hydrophobic property of cation-exchange resins affects monoclonal antibody aggregation. J Chromatogr A 2020; 1631:461573. [DOI: 10.1016/j.chroma.2020.461573] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 09/06/2020] [Accepted: 09/19/2020] [Indexed: 12/29/2022]
|
31
|
Holstein M, Jang D, Urrea C, Botta LS, Grimm W, Ghose S, Li ZJ. Control of leached beta-glucan levels from depth filters by an improved depth filtration flush strategy. Biotechnol Prog 2020; 37:e3086. [PMID: 33016571 DOI: 10.1002/btpr.3086] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 09/17/2020] [Accepted: 09/28/2020] [Indexed: 11/10/2022]
Abstract
Beta-glucans are polysaccharides of D-glucose monomers linked by (1-3) beta-glycosidic bonds, are found to have a potential immunogenicity risk in biotherapeutic products, and are labeled as process contaminants. A common source of beta-glucans is from the cellulose found in traditional depth filter media. Typically, beta-glucan impurities that leach into the product from the primary clarification depth filters can be removed by the subsequent bind-and-elute affinity chromatography capture step. Beta-glucans can also be removed by a bind-and-elute cation exchange chromatography step, which is useful for removing beta-glucans introduced by a post-Protein A depth filtration step. However, the increasing prevalence of flowthrough polishing chromatography poses a challenge for beta-glucan removal due to the lack of any bind-and-elute chromatography steps after the post-Protein A depth filter. In this work, a depth filter flush strategy was developed to control beta-glucan leaching into the product pool. Different loading conditions for the depth filtration and subsequent chromatography steps were evaluated to determine the robustness of the optimized flush strategy. Carry through runs demonstrated greater than two-fold reduction in beta-glucan levels using the optimized wash as compared to standard filter flush conditions.
Collapse
Affiliation(s)
- Melissa Holstein
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts, USA
| | - Dongyoun Jang
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts, USA
| | - Christine Urrea
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts, USA
| | - Lakshmi Sirisha Botta
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts, USA
| | - William Grimm
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts, USA
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts, USA
| |
Collapse
|
32
|
Li Y, Lock LL, Mills J, Ou BS, Morrow M, Stern D, Wang H, Anderson CF, Xu X, Ghose S, Li ZJ, Cui H. Selective Capture and Recovery of Monoclonal Antibodies by Self-Assembling Supramolecular Polymers of High Affinity for Protein Binding. Nano Lett 2020; 20:6957-6965. [PMID: 32852220 DOI: 10.1021/acs.nanolett.0c01297] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The separation and purification of therapeutic proteins from their biological resources pose a great limitation for industrial manufacturing of biologics in an efficient and cost-effective manner. We report here a supramolecular polymeric system that can undergo multiple reversible processes for efficient capture, precipitation, and recovery of monoclonal antibodies (mAbs). These supramolecular polymers, namely immunofibers (IFs), are formed by coassembly of a mAb-binding peptide amphiphile with a rationally designed filler molecule of varying stoichiometric ratios. Under the optimized conditions, IFs can specifically capture mAbs with a precipitation yield greater than 99%, leading to an overall mAb recovery yield of 94%. We also demonstrated the feasibility of capturing and recovering two mAbs from clarified cell culture harvest. These results showcase the promising potential of peptide-based supramolecular polymers as reversible affinity precipitants for mAb purification.
Collapse
Affiliation(s)
- Yi Li
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States
| | - Lye Lin Lock
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts 01434, United States
| | - Jason Mills
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts 01434, United States
| | - Ben S Ou
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States
| | - Marina Morrow
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States
| | - David Stern
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States
| | - Han Wang
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States
| | - Caleb F Anderson
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts 01434, United States
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts 01434, United States
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, Massachusetts 01434, United States
| | - Honggang Cui
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, Maryland 21218, United States
- Department of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, United States
| |
Collapse
|
33
|
Cura AJ, Xu X, Egan S, Aron K, Jenkins L, Hageman T, Huang Y, Chollangi S, Borys M, Ghose S, Li ZJ. Metabolic understanding of disulfide reduction during monoclonal antibody production. Appl Microbiol Biotechnol 2020; 104:9655-9669. [PMID: 32997205 DOI: 10.1007/s00253-020-10916-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2020] [Revised: 09/09/2020] [Accepted: 09/17/2020] [Indexed: 01/04/2023]
Abstract
The disulfide reduction of intact monoclonal antibodies (mAbs) and subsequent formation of low molecular weight (LMW) species pose a direct risk to product stability, potency, and patient safety. Although enzymatic mechanisms of reduction are well established, an understanding of the cellular mechanisms during the bioreactor process leading to increased risk of disulfide reduction after harvest remains elusive. In this study, we examined bench, pilot, and manufacturing-scale batches of two mAbs expressed in Chinese hamster ovary (CHO) cells, where harvested cell culture fluid (HCCF) occasionally demonstrated disulfide reduction. Comparative proteomics highlighted a significant elevation in glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels in a highly reducing batch of HCCF, compared to a non-reducing batch. Analysis during production cell culture showed that increased GAPDH gene and protein expression correlated to disulfide reduction risk in HCCF in every case examined. Additionally, glucose 6-phosphate dehydrogenase (G6PD) activity and an increased (≥ 300%) lactate/pyruvate molar ratio (lac/pyr) during production cell culture correlated to disulfide reduction risk, suggesting a metabolic shift to the pentose phosphate pathway (PPP). In all, these results suggest that metabolic alterations during cell culture lead to changes in protein expression and enzyme activity that in turn increase the risk of disulfide reduction in HCCF. KEY POINTS: • Bioreactor conditions resulted in reduction susceptible harvest material. • GAPDH expression, G6PD activity, and lac/pyr ratio correlated with mAb reduction. • Demonstrated role for cell metabolic changes in post-harvest mAb reduction. Graphical abstract.
Collapse
Affiliation(s)
- Anthony J Cura
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA
| | - Xuankuo Xu
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA.
| | - Susan Egan
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA
| | - Kathryn Aron
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA.
| | - Lauren Jenkins
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA
| | - Tyler Hageman
- Biophysical Characterization, Global Product Development and Supply, Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ, 08901, USA
| | - Yunping Huang
- Biophysical Characterization, Global Product Development and Supply, Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, NJ, 08901, USA
| | - Srinivas Chollangi
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA
| | - Michael Borys
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA
| | - Sanchayita Ghose
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA
| | - Zheng Jian Li
- Biologics Development, Global Product Development and Supply, Bristol-Myers Squibb Company, 38 Jackson Road, Devens, MA, 01434, USA
| |
Collapse
|
34
|
Chen G, Umatheva U, Pagano J, Yu D, Ghose S, Li Z, Ghosh R. High-resolution purification of a therapeutic PEGylated protein using a cuboid packed-bed device. J Chromatogr A 2020; 1630:461524. [PMID: 32920248 DOI: 10.1016/j.chroma.2020.461524] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 08/15/2020] [Accepted: 09/01/2020] [Indexed: 12/18/2022]
Abstract
PEGylated proteins which are a class of protein-synthetic polymer conjugates that have shown significant promise in the area of biotherapeutics are difficult to purify. A cuboid packed-bed device was used to purify a mono-PEGylated therapeutic protein from impurities such as high molecular weight (HMW) species (e.g., tri- and/or di-PEGylated forms), and low molecular weight (LMW) species such as unreacted protein and polyethylene glycol (or PEG). The separation efficiency of this device was compared with that of an equivalent cylindrical column. The effects of operating conditions such as flow rate, buffer composition, elution gradient, and column loading were systematically compared. An equivalent column with the same bed volume, same resin and same bed height was served as control. In mono-PEGylated protein purifications experiments, the cuboid packed-bed device exhibited sharper peaks and gave better resolution at all conditions examined in this study. The purity of mono-PEGylated protein in the samples collected from the cuboid packed-bed device and the column were comparable, i.e., 98.1% and 97.9% respectively. The recovery of mono-PEGylated protein in the pooled eluate from the cuboid packed-bed device was 31.7% greater than that recovered in the pooled eluate from the column. Therefore, significantly higher recovery of mono-PEGylated protein was obtained with the cuboid packed-bed device while maintaining the same purity specification as obtained with the column.
Collapse
Affiliation(s)
- Guoqiang Chen
- Department of Chemical Engineering, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L7, Canada
| | - Umatheny Umatheva
- Department of Chemical Engineering, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L7, Canada
| | - John Pagano
- Biologics Process Development, Bristol-Myers Squibb, 3510F-BDB231, 38 Jackson Road, Devens MA 01434, United States
| | - Deqiang Yu
- Biologics Process Development, Bristol-Myers Squibb, 3510F-BDB231, 38 Jackson Road, Devens MA 01434, United States
| | - Sanchayita Ghose
- Biologics Process Development, Bristol-Myers Squibb, 3510F-BDB231, 38 Jackson Road, Devens MA 01434, United States
| | - Zhengjian Li
- Biologics Process Development, Bristol-Myers Squibb, 3510F-BDB231, 38 Jackson Road, Devens MA 01434, United States
| | - Raja Ghosh
- Department of Chemical Engineering, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L7, Canada.
| |
Collapse
|
35
|
Wasalathanthri DP, Feroz H, Puri N, Hung J, Lane G, Holstein M, Chemmalil L, Both D, Ghose S, Ding J, Li ZJ. Real‐time monitoring of quality attributes by in‐line Fourier transform infrared spectroscopic sensors at ultrafiltration and diafiltration of bioprocess. Biotechnol Bioeng 2020; 117:3766-3774. [DOI: 10.1002/bit.27532] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 07/19/2020] [Accepted: 08/07/2020] [Indexed: 01/20/2023]
Affiliation(s)
| | - Hasin Feroz
- Biologics Process Development Bristol Myers Squibb Company Devens Massachusetts
| | - Neha Puri
- Biologics Process Development Bristol Myers Squibb Company Devens Massachusetts
| | - Jessica Hung
- Biologics Process Development Bristol Myers Squibb Company Devens Massachusetts
| | - Gregory Lane
- Engineering Technologies Bristol Myers Squibb Company New Brunswick New Jersey
| | - Melissa Holstein
- Biologics Process Development Bristol Myers Squibb Company Devens Massachusetts
| | - Letha Chemmalil
- Biologics Process Development Bristol Myers Squibb Company Devens Massachusetts
| | - Douglas Both
- Engineering Technologies Bristol Myers Squibb Company New Brunswick New Jersey
| | - Sanchayita Ghose
- Biologics Process Development Bristol Myers Squibb Company Devens Massachusetts
| | - Julia Ding
- Biologics Process Development Bristol Myers Squibb Company Devens Massachusetts
| | - Zheng Jian Li
- Biologics Process Development Bristol Myers Squibb Company Devens Massachusetts
| |
Collapse
|
36
|
Holstein M, Hung J, Feroz H, Ranjan S, Du C, Ghose S, Li ZJ. Strategies for high‐concentration drug substance manufacturing to facilitate subcutaneous administration: A review. Biotechnol Bioeng 2020; 117:3591-3606. [DOI: 10.1002/bit.27510] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 07/17/2020] [Accepted: 07/18/2020] [Indexed: 12/27/2022]
Affiliation(s)
- Melissa Holstein
- Biologics Process Development, Global Product Development and Supply Bristol‐Myers Squibb Co. Devens Massachusetts
| | - Jessica Hung
- Biologics Process Development, Global Product Development and Supply Bristol‐Myers Squibb Co. Devens Massachusetts
| | - Hasin Feroz
- Biologics Process Development, Global Product Development and Supply Bristol‐Myers Squibb Co. Devens Massachusetts
| | - Swarnim Ranjan
- Biologics Process Development, Global Product Development and Supply Bristol‐Myers Squibb Co. Devens Massachusetts
| | - Cheng Du
- Biologics Process Development, Global Product Development and Supply Bristol‐Myers Squibb Co. Devens Massachusetts
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply Bristol‐Myers Squibb Co. Devens Massachusetts
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply Bristol‐Myers Squibb Co. Devens Massachusetts
| |
Collapse
|
37
|
Xing Z, Jin W, Xu X, Song Y, Huang C, Borys MC, Ghose S, Li ZJ. A CFD model for predicting protein aggregation in low-pH virial inactivation for mAb production. Biotechnol Bioeng 2020; 117:3400-3412. [PMID: 32672835 DOI: 10.1002/bit.27505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 06/26/2020] [Accepted: 07/15/2020] [Indexed: 11/11/2022]
Abstract
Significant amounts of soluble product aggregates were observed in the low-pH viral inactivation (VI) operation during an initial scale-up run for an immunoglobulin-G 4 (IgG4) monoclonal antibody (mAb IgG4-N1). Being earlier in development, a scale-down model did not exist, nor was it practical to use costly Protein A eluate (PAE) for testing the VI process at scale, thus, a computational fluid dynamics (CFD)-based high-molecular weight (HMW) prediction model was developed for troubleshooting and risk mitigation. It was previously reported that the IgG4-N1 molecules upon exposure to low pH tend to change into transient and partially unfolded monomers during VI acidification (i.e., VIA) and form aggregates after neutralization (i.e., VIN). Therefore, the CFD model reported here focuses on the VIA step. The model mimics the continuous addition of acid to PAE and tracks acid distribution during VIA. Based on the simulated low-pH zone (≤pH 3.3) profiles and PAE properties, the integrated low-pH zone (ILPZ) value was obtained to predict HMW level at the VI step. The simulations were performed to examine the operating parameters, such as agitation speed, acid addition rate, and protein concentration of PAE, of the pilot scale (50-200 L) runs. The conditions with predictions of no product aggregation risk were recommended to the real scale-up runs, resulted in 100% success rate of the consecutive 12 pilot-scale runs. This study demonstrated that the CFD-based HMW prediction model could be used as a tool to facilitate the scale up of the low-pH VI process directly from bench to pilot/production scale.
Collapse
Affiliation(s)
- Zizhuo Xing
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, Massachusetts
| | - Weixin Jin
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, Massachusetts
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, Massachusetts
| | - Yuanli Song
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, Massachusetts
| | - Chao Huang
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, Massachusetts
| | - Michael C Borys
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, Massachusetts
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, Massachusetts
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, Massachusetts
| |
Collapse
|
38
|
Xu J, Xu X, Huang C, Angelo J, Oliveira CL, Xu M, Xu X, Temel D, Ding J, Ghose S, Borys MC, Li ZJ. Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study. MAbs 2020; 12:1770669. [PMID: 32425110 PMCID: PMC7531520 DOI: 10.1080/19420862.2020.1770669] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8) and 2000-L scales (Process C, n = 3) for the production of a monoclonal antibody by a Chinese hamster ovary cell line. For the upstream part of the process, we implemented an intensified seed culture scheme to enhance cell densities at the seed culture step (N-1) prior to the production bioreactor (N) by using either enriched N-1 seed culture medium for Process B or by operating the N-1 step in perfusion mode for Process C. The increased final cell densities at the N-1 step allowed for much higher inoculation densities in the production bioreactor operated in fed-batch mode and substantially increased titers by 4-fold from Process A to B and 8-fold from Process A to C, while maintaining comparable final product quality. Multiple changes were made to intensify the downstream process to accommodate the increased titers. New high-capacity resins were implemented for the Protein A and anion exchange chromatography (AEX) steps, and the cation exchange chromatography (CEX) step was changed from bind-elute to flow-through mode for the streamlined Process B. Multi-column chromatography was developed for Protein A capture, and an integrated AEX-CEX pool-less polishing steps allowed semi-continuous Process C with increased productivity as well as reductions in resin requirements, buffer consumption, and processing times. A cost-of-goods analysis on consumables showed 6.7–10.1 fold cost reduction from the conventional Process A to the intensified Process C. The hybrid-intensified process described here is easy to implement in manufacturing and lays a good foundation to develop a fully continuous manufacturing with even higher productivity in the future.
Collapse
Affiliation(s)
- Jianlin Xu
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Xuankuo Xu
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Chao Huang
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - James Angelo
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | | | - Mengmeng Xu
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Xia Xu
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Deniz Temel
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Julia Ding
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Sanchayita Ghose
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Michael C Borys
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| | - Zheng Jian Li
- Global Product Development and Supply, Bristol-Myers Squibb Company , Devens, MA, USA
| |
Collapse
|
39
|
Wasalathanthri DP, Rehmann MS, Song Y, Gu Y, Mi L, Shao C, Chemmalil L, Lee J, Ghose S, Borys MC, Ding J, Li ZJ. Technology outlook for real‐time quality attribute and process parameter monitoring in biopharmaceutical development—A review. Biotechnol Bioeng 2020; 117:3182-3198. [DOI: 10.1002/bit.27461] [Citation(s) in RCA: 45] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 05/30/2020] [Accepted: 06/11/2020] [Indexed: 12/11/2022]
Affiliation(s)
| | - Matthew S. Rehmann
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Yuanli Song
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Yan Gu
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Luo Mi
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Chun Shao
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Letha Chemmalil
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Jongchan Lee
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Sanchayita Ghose
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Michael C. Borys
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Julia Ding
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| | - Zheng Jian Li
- Biologics Process Development Bristol‐Myers Squibb Company Devens Massachusetts
| |
Collapse
|
40
|
Dautovich N, Ghose S. 0378 Social Well-Being as a Longitudinal Mediator of the Association Between Discrimination and Sleep Quality. Sleep 2020. [DOI: 10.1093/sleep/zsaa056.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Discrimination is a risk factor for poor sleep outcomes. Physiological activation is one mechanism tying the experience of discrimination to disturbed sleep. Discrimination, however, can also impact psychosocial well-being, which is a necessary precursor for healthy sleep. Feelings of safety derived from social connections can be threatened when individuals face discrimination. The objective of the current study was to examine the role of social well-being as a factor underlying the longitudinal association between discrimination and sleep quality.
Methods
An archival analysis was conducted with 937 adults participating in the longitudinal Midlife in the United States (MIDUS) study. Data was collected at three time points across 10 years. Perceived daily discrimination and overall social well-being were assessed via self-report. Sleep quality was assessed via the Pittsburgh Sleep Quality Index, Global Sleep Quality score.
Results
The overall model accounted for 15.6% of variance in global sleep quality. Controlling for multiple covariates, more frequent experiences of discrimination predicted worse global sleep quality 10 years later (β=.06, p=.03). Worse overall social well-being was a significant mediator of the discrimination-global sleep quality association (95% CI [.0001, .0118]), such that more frequent discrimination predicted lower overall social well-being, which, in turn, was associated with worse global sleep quality.
Conclusion
Given the persistence of sleep disparities among stigmatized and marginalized groups and the importance of sleep as a means of health disparity reduction, there is a need to identify mechanisms linking discrimination to poor sleep outcomes. Daily experiences of discrimination, such as being given less respect or treated as though less intelligent, have long-lasting associations with social well-being. Furthermore, social well-being is a predictor of future sleep quality. In addition to addressing discriminatory practices, targeting the effects of social well-being on sleep is a direction for future research.
Support
N/A
Collapse
Affiliation(s)
- N Dautovich
- Virginia Commonwealth University, Richmond, VA
| | - S Ghose
- Virginia Commonwealth University, Richmond, VA
| |
Collapse
|
41
|
Tan Z, Ehamparanathan V, Ren T, Tang P, Hoffman L, Kuang J, Liu P, Huang C, Du C, Tao L, Chemmalil L, Lewandowski A, Ghose S, Li ZJ, Liu S. On-column disulfide bond formation of monoclonal antibodies during Protein A chromatography eliminates low molecular weight species and rescues reduced antibodies. MAbs 2020; 12:1829333. [PMID: 33016217 PMCID: PMC7577237 DOI: 10.1080/19420862.2020.1829333] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 08/13/2020] [Accepted: 09/14/2020] [Indexed: 12/13/2022] Open
Abstract
Disulfide bond reduction, which commonly occurs during monoclonal antibody (mAb) manufacturing processes, can result in a drug substance with high levels of low molecular weight (LMW) species that may fail release specifications because the drug's safety and the efficiency may be affected by the presence of this material. We previously studied disulfide reoxidation of mAbs and demonstrated that disulfide bonds could be reformed from the reduced antibody via redox reactions under an optimal redox condition on Protein A resin. The study here implements a redox system in a manufacturing setting to rescue the reduced mAb product and to further eliminate LMW issues in downstream processing. As such, we incorporate the optimized redox system as one of the wash buffers in Protein A chromatography to enable an on-column disulfide reoxidation to form intact antibody in vitro. Studies at laboratory scale (1 cm (ID) x 20 cm (Height), MabSelect SuRe LX) and pilot scale (30 cm (ID) x 20 cm (Height), MabSelect SuRe LX) were performed to demonstrate the effectiveness and robustness of disulfide formation with multiple mAbs using redox wash on Protein A columns. By applying this rescue strategy using ≤50 g/L-resin loading, the intact mAb purity was improved from <5% in the Protein A column load to >90% in the Protein A column elution with a product yield of >90%. Studies were also done to confirm that adding the redox wash has no negative impact on process yield or impurity removal or product quality. The rescued mAbs were confirmed to form complete interchain disulfide bonds, exhibiting comparable biophysical properties to the reference material. Furthermore, since the redox wash is followed by a bridging buffer wash before the final elution, no additional burden is involved in removing the redox components during the downstream steps. Due to its ease of implementation, significant product purity improvement, and minimal impact on other product quality attributes, we demonstrate that the on-column reoxidation using a redox system is a powerful, simple, and safe tool to recover reduced mAb during manufacturing. Moreover, the apparent benefits of using a high-pH redox wash may further drive the evolution of Protein A platform processes.
Collapse
Affiliation(s)
- Zhijun Tan
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Vivekh Ehamparanathan
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Tingwei Ren
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Peifeng Tang
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
- Department of Paper and Bioprocess Engineering, The State University of New York College of Environmental Science and Forestry, Syracuse, NY, USA
| | - Laurel Hoffman
- Global Product Development and Supply, Bristol-Myers Squibb Company, Pennington, NJ, USA
| | - June Kuang
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Peiran Liu
- Global Product Development and Supply, Bristol-Myers Squibb Company, Pennington, NJ, USA
| | - Chao Huang
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Cheng Du
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Li Tao
- Global Product Development and Supply, Bristol-Myers Squibb Company, Pennington, NJ, USA
| | - Letha Chemmalil
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Angela Lewandowski
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Sanchayita Ghose
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Zheng Jian Li
- Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA, USA
| | - Shijie Liu
- Department of Paper and Bioprocess Engineering, The State University of New York College of Environmental Science and Forestry, Syracuse, NY, USA
| |
Collapse
|
42
|
Wälchli R, Ressurreição M, Vogg S, Feidl F, Angelo J, Xu X, Ghose S, Jian Li Z, Le Saoût X, Souquet J, Broly H, Morbidelli M. Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization. Biotechnol Bioeng 2019; 117:687-700. [PMID: 31784982 DOI: 10.1002/bit.27237] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Revised: 10/22/2019] [Accepted: 11/22/2019] [Indexed: 12/31/2022]
Abstract
Monoclonal antibodies (mAbs) and related recombinant proteins continue to gain importance in the treatment of a great variety of diseases. Despite significant advances, their manufacturing can still present challenges owing to their molecular complexity and stringent regulations with respect to product purity, stability, safety, and so forth. In this context, protein aggregates are of particular concern due to their immunogenic potential. During manufacturing, mAbs routinely undergo acidic treatment to inactivate viral contamination, which can lead to their aggregation and thereby to product loss. To better understand the underlying mechanism so as to propose strategies to mitigate the issue, we systematically investigated the denaturation and aggregation of two mAbs at low pH as well as after neutralization. We observed that at low pH and low ionic strength, mAb surface hydrophobicity increased whereas molecular size remained constant. After neutralization of acidic mAb solutions, the fraction of monomeric mAb started to decrease accompanied by an increase on average mAb size. This indicates that electrostatic repulsion prevents denatured mAb molecules from aggregation under acidic pH and low ionic strength, whereas neutralization reduces this repulsion and coagulation initiates. Limiting denaturation at low pH by d-sorbitol addition or temperature reduction effectively improved monomer recovery after neutralization. Our findings might be used to develop innovative viral inactivation procedures during mAb manufacturing that result in higher product yields.
Collapse
Affiliation(s)
- Ruben Wälchli
- Department of Chemistry and Applied Biosciences, ETH Zurich, Institute for Chemical and Bioengineering, Zurich, Switzerland
| | - Mariana Ressurreição
- Department of Chemistry and Applied Biosciences, ETH Zurich, Institute for Chemical and Bioengineering, Zurich, Switzerland
| | - Sebastian Vogg
- Department of Chemistry and Applied Biosciences, ETH Zurich, Institute for Chemical and Bioengineering, Zurich, Switzerland
| | - Fabian Feidl
- Department of Chemistry and Applied Biosciences, ETH Zurich, Institute for Chemical and Bioengineering, Zurich, Switzerland
| | - James Angelo
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Co., Devens, Massachusetts
| | - Xavier Le Saoût
- Biotech Process Sciences, Merck KGaA, Corsier-sur-Vevey, Vaud, Switzerland
| | - Jonathan Souquet
- Biotech Process Sciences, Merck KGaA, Corsier-sur-Vevey, Vaud, Switzerland
| | - Hervé Broly
- Biotech Process Sciences, Merck KGaA, Corsier-sur-Vevey, Vaud, Switzerland
| | - Massimo Morbidelli
- Department of Chemistry and Applied Biosciences, ETH Zurich, Institute for Chemical and Bioengineering, Zurich, Switzerland
| |
Collapse
|
43
|
Jin W, Xing Z, Song Y, Huang C, Xu X, Ghose S, Li ZJ. Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification. MAbs 2019; 11:1479-1491. [PMID: 31441367 PMCID: PMC6816434 DOI: 10.1080/19420862.2019.1658493] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 08/01/2019] [Accepted: 08/17/2019] [Indexed: 01/27/2023] Open
Abstract
Significant amounts of soluble product aggregates were observed during low-pH viral inactivation (VI) scale-up for an IgG4 monoclonal antibody (mAb IgG4-N1), while small-scale experiments in the same condition showed negligible aggregation. Poor mixing and product exposure to low pH were identified as the root cause. To gain a mechanistic understanding of the problem, protein aggregation properties were studied by varying critical parameters including pH, hold time and protein concentration. Comprehensive biophysical characterization of product monomers and aggregates was performed using fluorescence-size-exclusion chromatography, differential scanning fluorimetry, fluorescence spectroscopy, and dynamic light scattering. Results showed IgG4-N1 partially unfolds at about pH 3.3 where the product molecules still exist largely as monomers owing to strong inter-molecular repulsions and favorable colloidal stability. In the subsequent neutralization step, however, the conformationally changed monomers are prone to aggregation due to weaker inter-molecular repulsions following the pH transition from 3.3 to 5.5. Surface charge calculations using homology modeling suggested that intra-molecular repulsions, especially between CH2 domains, may contribute to the IgG4-N1 unfolding at ≤ pH 3.3. Computational fluid dynamics (CFD) modeling was employed to simulate the conditions of pH titration to reduce the risk of aggregate formation. The low-pH zones during acid addition were characterized using CFD modeling and correlated to the condition causing severe product aggregation. The CFD tool integrated with the mAb solution properties was used to optimize the VI operating parameters for successful scale-up demonstration. Our research revealed the governing aggregation mechanism for IgG4-N1 under acidic conditions by linking its molecular properties and various process-related parameters to macroscopic aggregation phenomena. This study also provides useful insights into the cause and mitigation of low-pH-induced IgG4 aggregation in downstream VI operation.
Collapse
Affiliation(s)
- Weixin Jin
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA, USA
| | - Zizhuo Xing
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA, USA
| | - Yuanli Song
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA, USA
| | - Chao Huang
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA, USA
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA, USA
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA, USA
| |
Collapse
|
44
|
Li Y, Stern D, Lock LL, Mills J, Ou SH, Morrow M, Xu X, Ghose S, Li ZJ, Cui H. Emerging biomaterials for downstream manufacturing of therapeutic proteins. Acta Biomater 2019; 95:73-90. [PMID: 30862553 DOI: 10.1016/j.actbio.2019.03.015] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 02/26/2019] [Accepted: 03/06/2019] [Indexed: 12/23/2022]
Abstract
Downstream processing is considered one of the most challenging phases of industrial manufacturing of therapeutic proteins, accounting for a large portion of the total production costs. The growing demand for therapeutic proteins in the biopharmaceutical market in addition to a significant rise in upstream titers have placed an increasing burden on the downstream purification process, which is often limited by high cost and insufficient capacities. To achieve efficient production and reduced costs, a variety of biomaterials have been exploited to improve the current techniques and also to develop superior alternatives. In this work, we discuss the significance of utilizing traditional biomaterials in downstream processing and review the recent progress in the development of new biomaterials for use in protein separation and purification. Several representative methods will be highlighted and discussed in detail, including affinity chromatography, non-affinity chromatography, membrane separations, magnetic separations, and precipitation/phase separations. STATEMENT OF SIGNIFICANCE: Nowadays, downstream processing of therapeutic proteins is facing great challenges created by the rapid increase of the market size and upstream titers, starving for significant improvements or innovations in current downstream unit operations. Biomaterials have been widely used in downstream manufacturing of proteins and efforts have been continuously devoted to developing more advanced biomaterials for the implementation of more efficient and economical purification methods. This review covers recent advances in the development and application of biomaterials specifically exploited for various chromatographic and non-chromatographic techniques, highlighting several promising alternative strategies.
Collapse
Affiliation(s)
- Yi Li
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - David Stern
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Lye Lin Lock
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA 01434, United States
| | - Jason Mills
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA 01434, United States
| | - Shih-Hao Ou
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Marina Morrow
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA 01434, United States.
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA 01434, United States
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Devens, MA 01434, United States
| | - Honggang Cui
- Department of Chemical and Biomolecular Engineering, and Institute for NanoBioTechnology, The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States; Department of Oncology and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, United States.
| |
Collapse
|
45
|
Yu D, Mayani M, Song Y, Xing Z, Ghose S, Li ZJ. Control of antibody high and low molecular weight species by depth filtration‐based cell culture harvesting. Biotechnol Bioeng 2019; 116:2610-2620. [DOI: 10.1002/bit.27081] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 05/24/2019] [Accepted: 06/06/2019] [Indexed: 02/06/2023]
Affiliation(s)
- Deqiang Yu
- Biologics Development, Global Manufacturing & SupplyBristol‐Myers Squibb Devens Massachusetts
| | - Mukesh Mayani
- Biologics Development, Global Manufacturing & SupplyBristol‐Myers Squibb Devens Massachusetts
| | - Yuanli Song
- Biologics Development, Global Manufacturing & SupplyBristol‐Myers Squibb Devens Massachusetts
| | - Zhizhuo Xing
- Biologics Development, Global Manufacturing & SupplyBristol‐Myers Squibb Devens Massachusetts
| | - Sanchayita Ghose
- Biologics Development, Global Manufacturing & SupplyBristol‐Myers Squibb Devens Massachusetts
| | - Zheng Jian Li
- Biologics Development, Global Manufacturing & SupplyBristol‐Myers Squibb Devens Massachusetts
| |
Collapse
|
46
|
Angelo J, Chollangi S, Müller‐Späth T, Jusyte S, Xu X, Ghose S, Li Z. Virus clearance validation across continuous capture chromatography. Biotechnol Bioeng 2019; 116:2275-2284. [DOI: 10.1002/bit.27012] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 04/11/2019] [Accepted: 05/02/2019] [Indexed: 11/11/2022]
Affiliation(s)
- James Angelo
- Biologics Process DevelopmentBristol‐Myers Squibb, IncDevens Massachusetts
| | - Srinivas Chollangi
- Biologics Process DevelopmentBristol‐Myers Squibb, IncDevens Massachusetts
| | | | - Simona Jusyte
- Viral Clearance Dept.WuXi Advanced Therapies UnitPhiladelphia Pennsylvania
| | - Xuankuo Xu
- Biologics Process DevelopmentBristol‐Myers Squibb, IncDevens Massachusetts
| | - Sanchayita Ghose
- Biologics Process DevelopmentBristol‐Myers Squibb, IncDevens Massachusetts
| | - Zhengjian Li
- Biologics Process DevelopmentBristol‐Myers Squibb, IncDevens Massachusetts
| |
Collapse
|
47
|
Abstract
Depth filtration is a commonly-used bioprocessing unit operation for harvest clarification that reduces the levels of process- and product-related impurities such as cell debris, host-cell proteins, nucleic acids and protein aggregates. Since depth filters comprise multiple components, different functionalities may contribute to such retention, making the mechanisms by which different impurities are removed difficult to decouple. Here we probe the mechanisms by which double-stranded DNA (dsDNA) is retained on depth filter media by visualizing the distribution of fluorescently-labeled retained DNA on spent depth filter discs using confocal fluorescence microscopy. The extent of DNA displacement into the depth filter was found to increase with decreasing DNA length with increasing operational parameters such as wash volume and buffer ionic strength. Finally, using 5ethynyl-2'-deoxyuridine (EdU) to label DNA in dividing CHO cells, we showed that Chinese hamster ovary (CHO) cellular DNA in the lysate supernatant migrates deeper into the depth filter than the lysate re-suspended pellet, elucidating the role of the size of the DNA in its form as an impurity. Apart from aiding DNA purification and removal, our experimental approaches and findings can be leveraged in studying the transport and retention of nucleic acids and other impurities on depth filters at a small scale.
Collapse
Affiliation(s)
- Ohnmar Khanal
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol‐Myers Squibb Company, Devens, MA 01434, USA
| | - Nripen Singh
- Biologics Process Development, Global Product Development and Supply, Bristol‐Myers Squibb Company, Devens, MA 01434, USA
| | - Steven J. Traylor
- Biologics Process Development, Global Product Development and Supply, Bristol‐Myers Squibb Company, Devens, MA 01434, USA
| | - Chao Huang
- Biologics Process Development, Global Product Development and Supply, Bristol‐Myers Squibb Company, Devens, MA 01434, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol‐Myers Squibb Company, Devens, MA 01434, USA
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol‐Myers Squibb Company, Devens, MA 01434, USA
| | - Abraham M. Lenhoff
- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA
| |
Collapse
|
48
|
Baur D, Angelo J, Chollangi S, Müller-Späth T, Xu X, Ghose S, Li ZJ, Morbidelli M. Model-assisted process characterization and validation for a continuous two-column protein A capture process. Biotechnol Bioeng 2018; 116:87-98. [DOI: 10.1002/bit.26849] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Revised: 10/03/2018] [Accepted: 10/05/2018] [Indexed: 12/16/2022]
Affiliation(s)
- Daniel Baur
- Department of Chemistry and Applied Biosciences; ETH Zürich; Zürich Switzerland
| | - James Angelo
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Inc; Devens Massachusetts
| | - Srinivas Chollangi
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Inc; Devens Massachusetts
| | | | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Inc; Devens Massachusetts
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Inc; Devens Massachusetts
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb, Inc; Devens Massachusetts
| | - Massimo Morbidelli
- Department of Chemistry and Applied Biosciences; ETH Zürich; Zürich Switzerland
| |
Collapse
|
49
|
Ghose S, Datta S. Knowledge, Attitude and Practices on Cancer Education and Prevention: A Cross-Sectional Survey. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.78902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: Lifestyle associated cancers are 1 of the top 5 leading causes of death in the world and India sees a million new cases yearly. Early detection is an effective way to reduce incidences and mortality for preventable cancers. There is significant delay in detection for a large proportion of cancer patients in India. Lack of awareness about cancer has been shown to be a major contributor to treatment delay in many countries. The current study looked at the cancer awareness in an urban Indian population to address the gap of information about cancer prevention. Aim: To quantify knowledge about cancer in an urban population and find sociodemographic associations of lack of knowledge. We also wanted to compare knowledge of people from general population with those having some knowledge due to a family member being under treatment. Methods: Data were collected from 2 stratums: family members of cancer patients, Internet using community from general population, non-Internet using community dwellers. Subject selection was randomized. A prevalidated questionnaire was used. Data were analyzed using STATA 13. Results: Respondents (n = 846) were family of cancer patients (n = 146, 17.3%), community dwellers (n = 175, 20.7%) and community Internet users (n = 525, 62.1%). No association of knowledge with age, gender, and income was found ( P values 0.84, 0.25, 0.93 respectively). Statistically significant association of cancer knowledge with education was found ( P < 0.001). There is significant difference in knowledge between Internet using and non-Internet using community ( P < 0.001). Conclusion: Education impacts cancer knowledge of the population. The population having access to Internet has a higher knowledge than nonusers; but exposure to cancer treatment does not result in higher knowledge on cancer. These results will inform prevention and health education policies and aid in designing awareness and screening programs for preventing cancer.
Collapse
Affiliation(s)
- S. Ghose
- Tata Medical Center, Medical Administration and Policy, Kolkata, India
| | - S.S. Datta
- Tata Medical Center, Palliative Care and Psycho Oncology, Kolkata, India
- University College London, Institute for Women's Health, London, United Kingdom
| |
Collapse
|
50
|
Greene DG, Traylor SJ, Guo J, Choe LH, Modla S, Xu X, Singh N, Lock LL, Ghose S, Li ZJ, Lee KH, Wagner NJ, Lenhoff AM. Mechanisms of precipitate formation during the purification of an Fc-fusion protein. Biotechnol Bioeng 2018; 115:2489-2503. [PMID: 29896879 PMCID: PMC6185765 DOI: 10.1002/bit.26746] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Revised: 05/08/2018] [Accepted: 06/05/2018] [Indexed: 12/24/2022]
Abstract
Protein precipitates that arise during bioprocessing can cause manufacturing challenges, but they can also aid in clearance of host-cell protein (HCP) and DNA impurities. Such precipitates differ from many protein precipitates that have been studied previously in their heterogeneous composition, particularly in the presence of high concentrations of the product protein. Here, we characterize the precipitates that form after neutralization of protein A purified and viral-inactivated material of an Fc-fusion protein produced in Chinese hamster ovary cells. The physical growth of precipitate particles was observed by optical microscopy, transmission electron microscopy, dynamic light scattering, and small-angle and ultra-small-angle X-ray scattering to characterize the precipitate microstructure and growth mechanism. The precipitate microstructure is well-described as a mass fractal with fractal dimension approximately 2. The growth is governed by a diffusion-limited aggregation mechanism as indicated by a power-law dependence on time of the size of the principal precipitate particles. Optical microscopy shows that these primary particles can further aggregate into larger particles in a manner that appears to be promoted by mixing. Absorbance experiments at varying pH and salt concentrations reveal that the growth is largely driven by attractive electrostatic interactions, as growth is hindered by an increase in ionic strength. The solution conditions that resulted in the most significant particle growth are also correlated with the greatest removal of soluble impurities (DNA and HCPs). Proteomic analysis of the precipitates allows identification of O ( 100 ) unique HCP impurities, depending on the buffer species (acetate or citrate) used for the viral inactivation. Most of these proteins have pI values near the precipitation pH, supporting the likely importance of electrostatic interactions in driving precipitate formation.
Collapse
Affiliation(s)
- Daniel G. Greene
- Department of Chemical and Biomolecular Engineering,University of Delaware, Newark, DE 19716, USA
| | - Steven J. Traylor
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA 01434, USA
| | - Jing Guo
- Department of Chemical and Biomolecular Engineering,University of Delaware, Newark, DE 19716, USA
| | - Leila H. Choe
- Department of Chemical and Biomolecular Engineering,University of Delaware, Newark, DE 19716, USA
| | - Shannon Modla
- Delaware Biotechnology Institute, Newark, DE 19711, USA
| | - Xuankuo Xu
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA 01434, USA
| | - Nripen Singh
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA 01434, USA
| | - Lye Lin Lock
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA 01434, USA
| | - Sanchayita Ghose
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA 01434, USA
| | - Zheng Jian Li
- Biologics Process Development, Global Product Development and Supply, Bristol-Myers Squibb Company, Devens, MA 01434, USA
| | - Kelvin H. Lee
- Department of Chemical and Biomolecular Engineering,University of Delaware, Newark, DE 19716, USA
- Delaware Biotechnology Institute, Newark, DE 19711, USA
| | - Norman J. Wagner
- Department of Chemical and Biomolecular Engineering,University of Delaware, Newark, DE 19716, USA
| | - Abraham M. Lenhoff
- Department of Chemical and Biomolecular Engineering,University of Delaware, Newark, DE 19716, USA
| |
Collapse
|